BACKGROUND: Patients with metastatic and muscle-invasive bladder cancer are commonly treated with cisplatin. A significant proportion of patients develop disease progression after an initial response to chemotherapy. Presently there is no standard of care for such patients. We examined whether pretreatment with an epigenetic agent would result in reversal of drug resistance. MATERIALS AND METHODS: Methylation of proapoptotic and cell cycle genes in bladder cancer cells was examined. Cisplatin- and docetaxel-resistant cells were generated. The effect of target of methylation-induced silencing (TMS1) expression and pretreatment of wild-type and drug-resistant cells with 5-azacytidine on chemosensitivity was determined. RESULTS: Unidirectional crossresistance of cisplatin-resistant UMUC3 cells to docetaxel was observed. Recombinant expression of TMS1 or pre-treatment of wild-type and drug-resistant cells with 5-azacytidine resulted in enhanced sensitivity to cisplatin and docetaxel. CONCLUSION: Our results indicate that epigenetic therapy may restore sensitivity to chemotherapeutic agents in bladder cancer cells.
BACKGROUND:Patients with metastatic and muscle-invasive bladder cancer are commonly treated with cisplatin. A significant proportion of patients develop disease progression after an initial response to chemotherapy. Presently there is no standard of care for such patients. We examined whether pretreatment with an epigenetic agent would result in reversal of drug resistance. MATERIALS AND METHODS: Methylation of proapoptotic and cell cycle genes in bladder cancer cells was examined. Cisplatin- and docetaxel-resistant cells were generated. The effect of target of methylation-induced silencing (TMS1) expression and pretreatment of wild-type and drug-resistant cells with 5-azacytidine on chemosensitivity was determined. RESULTS: Unidirectional crossresistance of cisplatin-resistant UMUC3 cells to docetaxel was observed. Recombinant expression of TMS1 or pre-treatment of wild-type and drug-resistant cells with 5-azacytidine resulted in enhanced sensitivity to cisplatin and docetaxel. CONCLUSION: Our results indicate that epigenetic therapy may restore sensitivity to chemotherapeutic agents in bladder cancer cells.
Authors: S Adi Harel; N Bossel Ben-Moshe; Y Aylon; D R Bublik; N Moskovits; G Toperoff; D Azaiza; F Biagoni; G Fuchs; S Wilder; A Hellman; G Blandino; E Domany; M Oren Journal: Cell Death Differ Date: 2015-01-16 Impact factor: 15.828
Authors: Stefan K Drexler; Luca Bonsignore; Mark Masin; Aubry Tardivel; Rene Jackstadt; Heiko Hermeking; Pascal Schneider; Olaf Gross; Jurg Tschopp; Amir S Yazdi Journal: Proc Natl Acad Sci U S A Date: 2012-10-22 Impact factor: 11.205
Authors: Daniel D Von Hoff; Drew W Rasco; Elisabeth I Heath; Pamela N Munster; Jan H M Schellens; Nicolas Isambert; Christophe Le Tourneau; Bert O'Neil; Ron H J Mathijssen; Jose A Lopez-Martin; W Jeff Edenfield; Miguel Martin; Patricia M LoRusso; Gordon L Bray; Jorge DiMartino; Aaron Nguyen; Kejian Liu; Eric Laille; Johanna C Bendell Journal: Clin Cancer Res Date: 2018-05-15 Impact factor: 12.531
Authors: Karoly Szepeshazi; Andrew V Schally; Gunhild Keller; Norman L Block; Daniel Benten; Gabor Halmos; Luca Szalontay; Irving Vidaurre; Miklos Jaszberenyi; Ferenc G Rick Journal: Oncotarget Date: 2012-07
Authors: Jean-Pierre Issa; Ignacio I Wistuba; Razelle Kurzrock; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta Journal: Clin Epigenetics Date: 2014-01-09 Impact factor: 6.551
Authors: Simon Crabb; Sarah J Danson; James W F Catto; Cathy McDowell; James N Lowder; Joshua Caddy; Denise Dunkley; Jessica Rajaram; Deborah Ellis; Stephanie Hill; David Hathorn; Amy Whitehead; Mihalis Kalevras; Robert Huddart; Gareth Griffiths Journal: Trials Date: 2018-04-03 Impact factor: 2.279